Lung Diseases, Interstitial Clinical Trial
Official title:
Assessment of Neuropsychiatric Function in Patients With Interstitial Lung Disease
Research on the impact of lung diseases on neuropsychological functioning has revealed impaired cognitive processing in patients with a variety of pulmonary disorders. While the mechanisms responsible for the association of pulmonary diseases and neurocognitive functioning remain unclear, some researchers have attributed it to reduced oxygenation of the brain. Early detection and accurate management of comorbidity have benefits in reducing ILD morbidity and mortality.
Research on the impact of lung diseases on neuropsychological functioning has revealed impaired cognitive processing in patients with a variety of pulmonary disorders. While the mechanisms responsible for the association of pulmonary diseases and neurocognitive functioning remain unclear, some researchers have attributed it to reduced oxygenation of the brain. Interstitial Lung Disease (ILD) is an "umbrella" term as it comprises a variety of pulmonary diseases which affect the interstitium (the tissue and space around the air sacs of the lungs). It may be caused by a variety of factors (namely, inhaled substances, medications, infection, connective tissue disease, malignancy or idiopathic reasons) and has a clear negative impact on patients' quality of life, leading to symptoms such as fatigue, dyspnea and coughing. Physical sequelae include reduced lung volumes due to tissue thickening, sometimes caused by inflammation. A further consequence is reduced breathing efficiency, resulting in reduced blood oxygen levels and compromised exercise capacity. Additionally, the fibrosis of the parenchyma impedes the level of gas exchange. A number of studies have reported mood effects in ILD, suggesting, however, that the diagnosis of depression may be obscured, due to the fatigue and apathy that is often a consequence of ILD. Early detection and accurate management of Neuropsychiatric comorbidities have benefits in reducing ILD morbidity and mortality. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04119115 -
Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
|
||
| Active, not recruiting |
NCT04559581 -
Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan
|
||
| Recruiting |
NCT05151640 -
INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
|
||
| Recruiting |
NCT02543073 -
MSC for Treatment of Interstitial Lung Disease After Allo-HSCT
|
Phase 1/Phase 2 | |
| Completed |
NCT02251964 -
Rituximab in Interstitial Pneumonitis
|
Phase 2/Phase 3 | |
| Terminated |
NCT01432080 -
Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant
|
Phase 2 | |
| Completed |
NCT01442779 -
Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Recruiting |
NCT05596760 -
Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers
|
N/A | |
| Recruiting |
NCT05866198 -
Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation
|
N/A | |
| Active, not recruiting |
NCT05321082 -
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
|
Phase 3 | |
| Completed |
NCT04016168 -
Idiopathic Pulmonary Fibrosis and Serum Bank
|
||
| Recruiting |
NCT00258583 -
Dorothy P. and Richard P. Simmons Center for ILD Research Registry
|
||
| Recruiting |
NCT05855109 -
Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors
|
||
| Recruiting |
NCT04159129 -
Effects of Pulmonary Rehabilitation on Walking Speed in Patients With COPD or ILD Patients
|
||
| Completed |
NCT03313180 -
A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis
|
Phase 3 | |
| Completed |
NCT05065190 -
A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis
|
Phase 3 | |
| Completed |
NCT03136120 -
Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease
|
||
| Recruiting |
NCT04930666 -
BREATHE ALD: A Shared Decision-Making Intervention for Adults With Advanced Lung Disease
|
||
| Recruiting |
NCT05503030 -
Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients
|
||
| Active, not recruiting |
NCT04702893 -
INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
|